Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma ...(ore frequent in theTEMODAR plus radiothe...),Health

Date:10/30/2007

ore frequent in the TEMODAR plus radiotherapy arm. The most common side effects across the cumulative TEMODAR experience were alopecia, nausea, vomiting, anorexia, headache and constipation. Forty-nine percent of patients treated with TEMODAR reported one or more severe or life-threatening events, most commonly fatigue, convulsions, headache and thrombocytopenia. Patients treated with TEMODAR Capsules may experience myelosuppression. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression. Grade 3/4 neutropenia (lab and AE combined) occurred in eight percent and Grade 3/4 thrombocytopenia in 14 percent of patients treated with temozolomide. In refractory anaplastic astrocytoma, Grade 3/4 neutropenia occurred in 14 percent and Grade 3/4 thrombocytopenia occurred in 19 percent of patients treated with temozolomide. TEMODAR Capsules are contraindicated in patients who have a history of hypersensitivity to any of its components, or to DTIC. Caution should be exercised when administered to those with severe hepatic or renal impairment.

TEMODAR may cause fetal harm when administered to a pregnant woman. Nursing should be discontinued in women receiving TEMODAR. The effectiveness of TEMODAR in children has not been established. TEMODAR Capsules should not be opened or chewed.

If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes. Prophylaxis against Pneumocystis carinii pneumonia (PCP) is required for all patients receiving concomitant TEMODAR and radiotherapy for the 42-day regimen. There may be a higher occurrence of PCP when temozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide, particularly patients receiving steroids, should be observed closely for the development of PCP regardless of the regimen.

Please see full prescr
'/>"/>

SOURCE Schering-Plough Corp. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
4. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
5. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
6. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
7. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
8. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. UCB Presents Long-Term CImzia Data in Crohns Disease
11. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week